1型强直性肌营养不良合并心房颤动患者口服达比加群酯后左心耳血栓完全溶解
Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation.
作者信息
Rago Anna, Papa Andrea Antonio, Arena Giulia, Mosella Marco, Cassese Antonio, Palladino Alberto, Golino Paolo
机构信息
Department of Cardiology, University of Campania "L. Vanvitelli", Monaldi Hospital, Naples, Italy.
Cardiomyology and Medical Genetics, University Hospital "L. Vanvitelli", Naples, Italy.
出版信息
Acta Myol. 2017 Dec 1;36(4):218-222. eCollection 2017 Dec.
Abstract
Myotonic Dystrophy type 1 (DM1) is the most common muscular dystrophy in adult life characterized by muscle dysfunction and cardiac conduction abnormalities. Atrial fibrillation frequently occurs in DM1 patients. It's related to the discontinuous and inhomogeneous propagation of sinus impulses and to the prolongation of atrial conduction time, caused by progressive fibrosis and fatty replacement of the myocardium. AF predisposes to a hyper-coagulable state and to an increased risk of thromboembolism. We report the first case of complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a myotonic dystrophy type I patient with atrial fibrillation scheduled for transesophageal echocardiogram-guided direct current cardioversion.
摘要
1型强直性肌营养不良（DM1）是成人中最常见的肌营养不良症，其特征为肌肉功能障碍和心脏传导异常。心房颤动在DM1患者中经常发生。它与窦性冲动的不连续和不均匀传播以及心房传导时间延长有关，这是由心肌的进行性纤维化和脂肪替代引起的。房颤易导致高凝状态和血栓栓塞风险增加。我们报告了首例使用口服达比加群酯使1型强直性肌营养不良合并心房颤动患者左心耳血栓完全溶解的病例，该患者计划接受经食管超声心动图引导下的直流电复律。
相似文献
1
Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation.1型强直性肌营养不良合并心房颤动患者口服达比加群酯后左心耳血栓完全溶解
Acta Myol. 2017 Dec 1;36(4):218-222. eCollection 2017 Dec.
2
Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation.RE-LATED AF-AFNET 7试验的原理与设计：左心耳血栓溶解——达比加群对房颤患者的影响
Clin Res Cardiol. 2016 Jan;105(1):29-36. doi: 10.1007/s00392-015-0883-7. Epub 2015 Jun 25.
3
Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy.1型强直性肌营养不良症与肺栓塞：达比加群酯治疗成功溶解血栓
Acta Myol. 2018 Sep 1;37(3):227-231. eCollection 2018 Sep.
4
Dabigatran Therapy Resulting in the Resolution of Rivaroxaban-resistant Left Atrial Appendage Thrombi in Patients with Atrial Fibrillation.达比加群治疗导致心房颤动患者中对利伐沙班耐药的左心耳血栓溶解
Intern Med. 2017;56(15):1977-1980. doi: 10.2169/internalmedicine.56.8508. Epub 2017 Aug 1.
5
Outcome of non-vitamin K oral anticoagulants in the treatment of left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.非维生素 K 口服抗凝剂治疗非瓣膜性心房颤动患者左心房/左心耳血栓的疗效。
J Cardiovasc Electrophysiol. 2020 Mar;31(3):658-663. doi: 10.1111/jce.14365. Epub 2020 Feb 4.
6
Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography.经胸和经食管超声心动图评估达比加群酯对心房颤动患者左心耳血栓的抗凝疗效
Medicine (Baltimore). 2018 Jun;97(26):e11117. doi: 10.1097/MD.0000000000011117.
7
Is Dabigatran As Effective As Warfarin on Cardiac Thrombus in a Patient With Atrial Fibrillation? A Challenging Question.达比加群在房颤患者中预防心脏血栓形成的效果与华法林相当吗？一个具有挑战性的问题。
Am J Ther. 2016 May-Jun;23(3):e974-6. doi: 10.1097/MJT.0000000000000129.
8
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study.生物瓣膜置换术后房颤管理中达比加群与华法林的比较：DAWA 初步研究
Drugs R D. 2016 Jun;16(2):149-54. doi: 10.1007/s40268-016-0124-1.
9
Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.达比加群酯：非瓣膜性心房颤动的研究进展。
Drugs. 2017 Mar;77(3):331-344. doi: 10.1007/s40265-017-0699-z.
10
Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report.达比加群作为对利伐沙班耐药的心房血栓形成的替代治疗：一例报告。
Medicine (Baltimore). 2018 Dec;97(51):e13623. doi: 10.1097/MD.0000000000013623.
引用本文的文献
1
Heart transplantation in a patient with Myotonic Dystrophy type 1 and end-stage dilated cardiomyopathy: a short term follow-up.1型强直性肌营养不良合并终末期扩张型心肌病患者的心脏移植：短期随访
Acta Myol. 2018 Dec 1;37(4):267-271. eCollection 2018 Dec.
2
Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy.1型强直性肌营养不良症与肺栓塞：达比加群酯治疗成功溶解血栓
Acta Myol. 2018 Sep 1;37(3):227-231. eCollection 2018 Sep.
本文引用的文献
1
Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.达比加群酯在拟行经食管超声心动图引导直流电复律的心房颤动患者中的疗效和安全性：一项前瞻性倾向评分匹配队列研究。
J Thromb Thrombolysis. 2018 Feb;45(2):206-212. doi: 10.1007/s11239-017-1599-5.
2
Use of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review.非维生素 K 拮抗剂口服抗凝剂在恶性肿瘤合并心房颤动患者中的应用：单中心临床实践经验及文献复习。
Semin Thromb Hemost. 2018 Jun;44(4):370-376. doi: 10.1055/s-0037-1607436. Epub 2017 Dec 8.
3
NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world.NOACs 和心房颤动：真实世界中左心房血栓形成的发生率及预测因素。
Int J Cardiol. 2017 Dec 15;249:179-183. doi: 10.1016/j.ijcard.2017.07.048.
4
The clinical performance of dabigatran in the Italian real-life experience.达比加群酯在意大利真实临床应用中的表现。
J Cardiovasc Med (Hagerstown). 2017 Nov;18(11):922-923. doi: 10.2459/JCM.0000000000000548.
5
Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert Economic Study.利伐沙班与华法林抗凝策略用于非瓣膜性心房颤动患者直流电复律的预算影响分析：莫纳尔迪弗特经济学研究
Minerva Cardioangiol. 2018 Feb;66(1):1-5. doi: 10.23736/S0026-4725.17.04500-5. Epub 2017 Sep 25.
6
Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence.特异性口服抗凝剂用于心房颤动卒中预防的疗效与安全性：真实世界证据
Ther Adv Drug Saf. 2017 Feb;8(2):67-75. doi: 10.1177/2042098616673990. Epub 2016 Oct 24.
7
The role of the atrial electromechanical delay in predicting atrial fibrillation in beta-thalassemia major patients.心房电机械延迟在预测重型β地中海贫血患者心房颤动中的作用。
J Interv Card Electrophysiol. 2017 Mar;48(2):147-157. doi: 10.1007/s10840-016-0201-y. Epub 2016 Nov 22.
8
A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience.在非瓣膜性心房颤动患者中使用短期利伐沙班给药进行直流电复律的新综合策略：莫纳尔迪复律（MonaldiVert）的真实生活经验
Int J Cardiol. 2016 Dec 1;224:454-455. doi: 10.1016/j.ijcard.2016.09.022. Epub 2016 Sep 15.
9
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
10
Sudden cardiac death in neuromuscolar disorders: Time to establish shared protocols for cardiac pacing.神经肌肉疾病中的心脏性猝死：是时候建立心脏起搏的共享协议了。
Int J Cardiol. 2016 Mar 15;207:284-5. doi: 10.1016/j.ijcard.2016.01.175. Epub 2016 Jan 13.
Zotero 插件